About GSK
GSK is a Healthcare company based in Plymouth (United States) founded in 2022 by Nicholas Lydon, George Demetri, and Alexis Borisy, and was acquired by GSK in January 2025. Precision combination therapies for cancer drivers are developed by IDRx. It operates on a Direct-to-Consumer (D2C) and Professional Services model. GSK has raised $242 million across 2 funding rounds from investors including Blackstone, Merck and RA Capital. GSK offers products and services including Respiratory Treatments, Oncology Therapies, HIV Medications, and Infectious Disease Solutions. Its focus areas include Pharmaceuticals and Biopharmaceuticals. Its legal entity is GSK plc. Its competitors include Intima Bioscience, Ilico Genetics and Kupffer Biotherapeutics; 1 of its 3 listed competitors has raised funding.
Company details
GSK, a leading biopharmaceutical company, is focused on uniting science, technology, and talent to address diseases. Operations are centered in therapeutic areas such as respiratory, immunology, oncology, HIV, and infectious diseases. Solutions are developed to improve global health access, particularly in lower-income regions. Commitment is shown towards environmental sustainability and ethical standards. Research and development efforts are prioritized to innovate treatments and positively impact 2.5 billion people by the decades end.
- Total Equity Funding$242M (USD)
in 2 rounds
- Latest Funding Round$120M (USD), Series B
Aug 2024
- InvestorsBlackstone
& 10 more
- Acquired byGSK
(Jan 2025)
Products & Services of GSK
GSK offers a comprehensive portfolio of products and services, including Respiratory Treatments, Oncology Therapies, HIV Medications, and Infectious Disease Solutions.
Solutions for respiratory conditions are developed and provided.
Cancer treatments are researched and offered for patients.
HIV therapies are created to manage the condition.
Treatments for infectious diseases are developed and distributed.
Apps and channels of GSK
its YouTube channel ViiV Healthcare has 133 subscribers and 30 videos.
Videos from GSK
The most watched videos on GSK's YouTube channel, ViiV Healthcare (133 subscribers). Click a video to play it here.
More on ViiV Healthcare.
Funding Insights of GSK
GSK has successfully raised a total of $242M across 2 strategic funding rounds. The most recent funding activity was a Series B round of $120 million completed in August 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $242M
- Total Rounds 2
- Last Round Series B β $120M
- First Round $122M
(Aug 2022)
- Investors Count 10
All 2 funding rounds of GSK with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Aug 2024 | $120M | Series B | β | RA Capital Management | |
| Aug 2022 | $122M | Series A | β | a16z, Casdin Capital | β |
11 investors in total: 11 institutional.
Investors in GSK
GSK has secured backing from 11 investors, including institutional and venture fund investors. Prominent investors backing the company include Blackstone, Merck and RA Capital.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Venture capital is provided to healthcare startups by Commodore Capital. | commodorecapital.com | New York, United States | ||
Diversified investment management is provided across multiple asset classes. | 1985 | blackstone.com | New York, United States | |
Early-stage and late-stage biotech and finance companies are funded. | rockspringscapital.com | Baltimore, United States | ||
Venture capital investments in technology sectors are handled by Andreessen Horowitz. | a16z.com | |||
Investing in Life Sciences sectors like Healthcare and Biotechnology. | casdincapital.com | |||
PE firm investing in the US | nextechinvest.com | Zurich, Switzerland | ||
Limited information is provided about Forge Life Science Partners. | forgelsp.com | |||
RA Capital is engaged in evidence-based investing in healthcare and life sciences. | 2004 | racap.com | Boston, United States | |
Merck is engaged in science and technology solutions globally. | 1668 | merckgroup.com | Darmstadt, Germany | |
Evrys Bio is focused on developing broad-spectrum antiviral therapies. | forgelifescience.com | Doylestown, United States |
Investor details for GSK
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of GSK
5 people are tracked at GSK (3 in leadership, 2 in team).
| Name | Role | Group |
|---|---|---|
Nicholas Lydon | Co-Founder | Leadership |
George Demetri | Co-Founder | Leadership |
Alexis Borisy | Co-Founder | Leadership |
Jorge Conde | Board Member | Team |
Vivek Kadambi | Senior Advisor | Team |
Complete people profiles for GSK
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of GSK
4 dated milestones of GSK across 3 years, from founding to its latest funding, stage changes and deals.
- Founded GSK is founded.
- Funding First funding round of $122.0M.
- Funding Latest funding round, Series B, of $120.0M.
- Exit Acquired by GSK.
Competitors of GSK
GSK has 3 listed competitors in our database, 1 of them funded. They include Intima Bioscience, Ilico Genetics and Kupffer Biotherapeutics.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| intimabioscience.com | 2014 | New York, United States | Therapeutics for gastrointestinal cancer are developed using CRISPR gene-editing. | |||
| ilicogenetics.com | 2020 | Bethlehem, United States | $457,735 | Developer of diagostic test for detection of gastric cancer | ||
| kupfferbio.com | 2019 | Burlingame, United States | Develops innovative technologies for anticancer therapies targeting gastrointestinal cancers. |
Detailed competitors of GSK
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Oncology
3 companies that operate in the same segment as GSK (Oncology) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 4,867 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 2 B | USD 147.17 M | 1,141 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track β from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Gsk
Complete news archive for GSK
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about GSK
GSK was founded in 2022.
GSK is headquartered in Plymouth, United States. It is registered at Plymouth, Massachusetts, United States.
GSK is a funded company, having raised a total of $242M across 2 funding rounds to date. The company's 1st funding round was a Series A of $122M, raised on Aug 2022.
GSK, a leading biopharmaceutical company, is focused on uniting science, technology, and talent to address diseases. Operations are centered in therapeutic areas such as respiratory, immunology, oncology, HIV, and infectious diseases. Solutions are developed to improve global health access, particularly in lower-income regions. Commitment is shown towards environmental sustainability and ethical standards. Research and development efforts are prioritized to innovate treatments and positively impact 2.5 billion people by the decades end.
GSK's top competitors include Ilico Genetics, Intima Bioscience and Kupffer Biotherapeutics.
GSK offers Respiratory Treatments, Oncology Therapies, HIV Medications, and Infectious Disease Solutions.
GSK has 11 investors. Key investors include Blackstone, Merck, RA Capital, GSK, and Commodore Capital.
GSK operates through Gsk Plc.
Yes. GSK was acquired by GSK in January 2025.

